Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2019-08-06 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 July 2019
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/7/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related activities. The content focuses on changes in the company's share capital structure during the month, including share issuance, options exercised, and other capital changes. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory filing reporting share capital movements, typical of a capital/financing update. It is not an announcement of a report publication, nor a full financial report, nor a voting result or management change. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length and detail support a high confidence classification.
2019-08-06 English
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPROVAL FOR ASC18 AND MANAGEMENT OUTLOOK OF 2019 AND BEYOND
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the approval of an investigational new drug (IND) for ASC18 and the management's outlook for 2019 and beyond. It is a short announcement (1998 characters) and does not contain detailed financial data, comprehensive management discussion, or full financial statements. It is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or audit report. The document is an update on a regulatory approval and management outlook, which fits best under a general regulatory announcement category. It is not a report publication announcement since it does not mention the release or availability of a report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-08-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/7/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related capital changes. The content is focused on share capital changes and movements rather than financial performance, management discussion, or earnings. It is a regulatory filing reporting monthly share capital movements to the exchange, consistent with a capital/financing update or share capital change disclosure. Given the detailed nature of share capital movements and the monthly frequency, this fits best under the category 'Share Issue/Capital Change' (SHA). The document length is substantial and contains detailed data, not just an announcement or a brief notice, so it is not a report publication announcement or a regulatory filing fallback. Therefore, the classification is SHA with high confidence.
2019-08-02 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2018
Environmental & Social Information Classification · 100% confidence The document is titled 'Environmental, Social and Governance Report 2018' and contains detailed sections on governance system, innovation, stakeholder engagement, and environmental protection. It explicitly states it is an ESG report prepared according to the Environmental, Social and Governance Reporting Guide of the Hong Kong Stock Exchange. The content focuses on corporate social responsibility, governance, environmental protection, and social factors rather than financial performance or audit results. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement. Therefore, the document fits the category of Environmental & Social Information (SR).
2019-07-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2019
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/6/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on share capital changes and confirmations related to securities issuance, not on financial performance, management changes, or earnings. It is a regulatory filing reporting monthly share capital movements to the stock exchange, consistent with a capital/financing update or a regulatory filing. Given the detailed nature and regulatory submission context, it fits best under Capital/Financing Update (CAP).
2019-07-03 English
Monthly Return of Equity issuer on movements in Securities for the month ended 30 June 2019
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/6/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory filing reporting share capital movements, typical of a capital/financing update. It is not an announcement of a report, nor a full financial report, nor a certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-07-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.